For decades, a widespread hormonal disorder in women has been burdened with a scientifically inaccurate, vague, and distressing name for patients. Fortunately, this reality is finally changing.<\/p>\n
Polycystic Ovary Syndrome, almost universally known as PCOS, affects more than 170 million women of reproductive age. This condition is considered one of the most common hormonal disorders globally. Nevertheless, over 70% of those affected remain undiagnosed. Meanwhile, those who have received a diagnosis often spend years trying to understand why their actual symptoms do not fit the framework suggested by the name.<\/p>\n
As it turns out, this discrepancy is not accidental. The problem lies in the terminology itself. The established perception of PCOS\u2014that the problem consists solely of cysts in the ovaries\u2014does not correspond to reality. In truth, pathological cysts do not form at all, nor is the condition limited to a local disorder of the reproductive organs. Its impact is far broader, encompassing metabolism, cardiovascular function, mental health, and skin health.<\/p>\n
Following years of effort and a global consensus, the condition has been renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS. Published in the scientific journal The Lancet<\/i>, this change is considered one of the most significant breakthroughs in the nomenclature of women’s health in modern medical history.<\/p>\n To understand the significance of the name change, a deep comprehension of the nature of PMOS (formerly PCOS) is essential.<\/p>\n This condition represents a kind of chain reaction of hormonal imbalances. It often begins with insulin resistance, which manifests in 85% of patients (including lean women). This imbalance drives the body to produce excess androgens\u2014”male hormones”\u2014which in turn cause acne and hirsutism (excess hair growth). Simultaneously, hormonal signals from the brain become disrupted, halting the natural ovulation cycle. It is because of this disruption that small, immature follicles accumulate in the ovaries. This image captured on ultrasound, which was mistakenly identified as “cysts,” is actually just follicles that have stalled in their development.<\/p>\n Beyond the reproductive system, individuals with PMOS face an increased risk of Type 2 diabetes, cardiovascular and liver diseases, hypertension, abnormal cholesterol levels, and sleep apnea. Statistics paint an even more alarming picture: compared to healthy women, the risk of heart attack increases by 150%, and the probability of stroke by 71%. Physical symptoms are often accompanied by psychological pressure, including depression, anxiety, and eating disorders.<\/p>\n Unfortunately, the old term “Polycystic Ovary Syndrome” did not hint at these complex risks at all. A name focused on only one organ and one narrow pathology failed to reflect the true condition. This misleading emphasis caused confusion among patients and led clinicians to ignore metabolic issues. Researchers even struggled to secure funding, as the name left the scientific community with the impression of a superficial, localized disorder. For the patients themselves, the term was a source of additional stress, as it focused exclusively on reproductive function\u2014particularly in cultures where fertility carries decisive social weight.<\/p>\n The flaws regarding the name were not a new discovery. As early as 2012, the U.S. National Institutes of Health (NIH) issued an official recommendation to change the name. For years, experts, patient groups, and researchers unanimously pointed out that the existing term was inaccurate and misleading.<\/p>\n While changing a name might seem simple, transforming a medical term on a global scale involved immense difficulties. Earlier attempts failed due to a lack of international coordination, a unified strategy, and broad engagement.<\/p>\n The process was further complicated by the criteria for selecting a new name, which had to be culturally acceptable as well as scientifically accurate. One serious contender was “Endocrine Metabolic Ovulatory Syndrome.” This term perfectly integrated the three main aspects of the disease: hormones, metabolism, and ovulation. However, its abbreviation\u2014EMOS\u2014was rejected due to its overlap with a youth subculture. Specialists believed such a resemblance would undermine the scientific authority of the diagnosis and complicate information retrieval in search engines. Due to these cultural and technical barriers, previous attempts ended unsuccessfully.<\/p>\n The current success surpassed previous attempts in scale and scientific rigor. Led by Monash University, Verity, and other international organizations, the initiative brought together thousands of patients and specialists worldwide.<\/p>\n The process involved several fundamental stages. A multilingual global survey gathered the opinions of over 14,000 people. Simultaneously, representatives from different continents and disciplines participated in international online workshops. Patients were not just consultants here\u2014they led every step of the process. Their primary demand was the elimination of stigma, while specialists sought scientific precision.<\/p>\n To select the new name, a marketing agency conducted cultural and linguistic analyses. The final decision was based on four principles: accuracy, simplicity, freedom from stigma, and cultural suitability. Thus, Polyendocrine Metabolic Ovarian Syndrome (PMOS) was formed, receiving support from the overwhelming majority of participants.<\/p>\n Examining each component of the new name helps in understanding the true nature of the condition:<\/p>\n The term Polyendocrine<\/b> indicates that the disease affects various hormonal pathways simultaneously. This condition is not a localized disorder of a single organ. It frames the disruption of the communication chain between the brain and the ovaries, the overproduction of androgenic hormones, and impaired insulin metabolism as a unified system. Scientific evidence also confirms that PMOS has a polygenic nature, explained by the combined action of many different genes.<\/p>\n Metabolic<\/b> highlights the crucial aspect that the old name failed to mention entirely. Metabolic disruption is not just a side effect of this syndrome; it is its central axis. Insulin resistance is directly linked to increased androgen levels, while the accumulation of excess adipose tissue in the abdominal area further complicates the course of the disease. Because of this metabolic chain, cardiovascular risks are considered an integral part of the condition.<\/p>\n The Ovarian<\/b> component confirms that the organ is involved in the process, though not in the form of cysts. The main problem here is the improper development of follicles and the disruption of ovulation. It is this dysfunction that causes irregular cycles and the specific ultrasound image that was erroneously labeled “polycystic.”<\/p>\n Regarding symptoms such as acne, hair loss, or psycho-emotional difficulties, these remain of critical importance to patient well-being. However, because these signs are secondary manifestations of hormonal imbalances, specialists did not consider it necessary to reflect them separately in the name.<\/p>\n The name change is only the initial stage of the process, which will be followed by a three-year, eight-step global implementation strategy.<\/p>\n This plan involves multifaceted systemic changes. Educational materials for patients and clinicians are being developed in various languages, while the new terminology is being integrated into electronic records and medical coding systems. Concurrently, active work is underway with the World Health Organization to reflect the new name in the International Classification of Diseases (ICD). Scientific journals, pharmaceutical companies, and universities are also participating, leading to the update of curricula and textbooks. The International PCOS Guideline, currently used in 195 countries, will be updated with the new terminology by 2028.<\/p>\n Despite the scale, researchers acknowledge certain limitations of the process. Engagement from some regions in Asia, Africa, and South America was lower than initially planned. Additionally, the non-random selection principle posed a certain risk of subjectivity. However, since the data received from different regions significantly overlapped, the result possesses strong global validity.<\/p>\n For years, over 170 million people lived with a diagnosis whose name masked real problems more than it explained them. For many patients, the diagnostic process was fraught with uncertainty and ignored symptoms, leaving their long-term health questions unanswered.<\/p>\n Of course, transforming PCOS into PMOS cannot automatically cure the disease. This change will not instantly fix delayed diagnostics or make metabolic and psychological difficulties disappear. However, it is a fundamental step forward, based on the most large-scale and internationally agreed-upon consensus in medical history.<\/p>\n This transformation is a sign that the medical field is ready to update its terminology in accordance with scientific progress. The new name provides patients, doctors, and researchers with a much fairer and more accurate foundation for perceiving this common hormonal disorder. The condition has already received its new name; given its true essence, a new stage of work and treatment is only just beginning.<\/p>\nWhat Was Actually Wrong With the Old Name<\/strong><\/h5>\n
Why the Name Didn’t Change Until Now<\/strong><\/h5>\n
How Was PMOS Selected?<\/strong><\/h5>\n
What Does the New Name Actually Mean?<\/strong><\/h5>\n
What Comes Next<\/strong><\/h5>\n
The Beginning of a New Phase<\/strong><\/h5>\n